Login to Your Account



DEALS AND M&A NEWS

With "our crown jewel back in our hands and the opportunity to bring it all the way to the market," Symphogen A/S found cause to celebrate, said CEO Kirsten Drejer, as the firm makes plans to finish the phase IIb trial begun by Merck KGaA with Sym004.

UP FIRST: PD-L1, IRAK4 ORALS

As company backers await data from the phase I trial with CUDC-907, due in June at the American Society of Clinical Oncology (ASCO), Curis Inc. signed an immuno-oncology deal that could be worth more than $100 million to Aurigene Discovery Technologies Ltd.

Just last week, Celgene Corp.'s head of business development, George Golumbeski, told a packed breakout session at the annual J.P. Morgan Healthcare Conference in San Francisco that the firm's long-term pipeline "can never be big enough."

More DEALS AND M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: